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Introduction: Genetic characterization of malignant meso-
thelioma shows a homozygous deletion of the INK4A/ARF 
locus, which results in inactivation of the p53 pathways.
Methods: We examined possible antitumor effects of adenovi-
ruses with a deletion of the E1B-55kD gene (Ad-delE1B55) 
on mesothelioma and investigated combinatory actions with 
the first-line chemotherapeutic agents.
Results:  Ad-delE1B55 produced cytotoxicity on mesothe-
lioma cells, which was associated with p53 phosphoryla-
tion, pRb dephosphorylation, and cleavage of caspases. 
Ad-delE1B55–infected cells displayed hyperploidy at the 
cell-cycle analysis and showed enlarged nuclear configura-
tions. Combination of Ad-delE1B55 plus cisplatin or peme-
trexed produced antitumor effects in vitro. Furthermore, 
Ad-delE1B55 and cisplatin showed combinatory effects in an 
orthotopic animal model.
Conclusions: Cell death caused by Ad-delE1B55 is attribut-
able to cell-cycle arrest at M-phase checkpoint followed by 
activated apoptotic pathways, and combination of the first-
line chemotherapeutic agents and the oncolytic adenovirus is 
a potential therapeutic for mesothelioma.
Key Words: Mesothelioma, Adenovirus, E1B-55 kDa, Chemotherapy, 
Hyperploidy.
(J Thorac Oncol. 2012;7: 1850–1857)
Malignant mesothelioma, often associated with asbestos exposure, develops in the thoracic cavity. The latent 
period is beyond 30 years, and no preventive method after 
the exposure is currently available.1 Early-stage patients can 
be subjected to radical surgical procedures, which neverthe-
less result in recurrence at a high frequency. Mesothelioma 
is resistant to radiotherapy and consequently chemotherapy is 
the primary treatment in most of the cases. A combination of 
cisplatin (CDDP) and pemetrexed (PEM) is currently the first-
line regimen, but the average survival time with this combina-
tion is only 12.1 months.2 The prognosis remains poor despite 
recent therapeutic modalities, and a novel strategy is required 
to improve the patient’s quality of life.
Gene therapy is a possible strategy and has advantages 
in mesothelioma treatments. Mesothelioma in the pleural 
cavity is easily accessible for vectors, and consistent lung 
movements make the vectors spread into multiple sites. 
There have been several kinds of phase I clinical trials for 
mesothelioma with replication-deficient adenoviruses (Ad) 
expressing either herpes simplex-thymidine kinase3 or inter-
feron-ß gene.4 The trials confirmed safety of intrapleural Ad 
delivery, but these vectors transduced only a small fraction 
of the tumors. A vector system with enhanced efficacy is 
thereby preferable.
Replication-competent Ad continuously release the 
progenies from infected tumors and consequently circumvent 
low transduction efficacy. This replicable propensity enhances 
the cytotoxicity, although host immunity is inhibitory to 
the viral spreading. Ad lacking the E1B-55 kDa molecules 
(Ad-delE1B55) are replication competent and were originally 
hypothesized to target only p53-mutated or -null tumors 
because of the defect in p53-inactivating E1B-55 kDa protein.5 
However, subsequent studies showed that the replication 
was not linked with the p53 genetic status.6 Nevertheless, 
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Ad-delE1B55 demonstrated greater cytotoxicity to p53-
mutated tumors than wild-type p53 tumors.7
The majority of mesothelioma clinical specimens are 
defective of the INK4A/ARF locus containing the p14ARF 
and the p16INK4A genes but possess the wild-type p53 gene.8 
Because p14ARF blocks Mdm2-mediated p53 degradation and 
p16INK4A inhibits cyclin-dependent kinases (CDK), the dele-
tion results in loss of p53 functions and pRB phosphorylation, 
which subsequently leads to uncontrolled cell proliferation 
with enhanced resistance to apoptotic stimuli. Previous stud-
ies showed that forced expression of p14ARF or p16INK4A inhib-
ited cell growth and induced apoptosis in mesothelioma.9,10 
Ad-delE1B55 can be a therapeutic agent in terms of the dis-
tinct genetic background of mesothelioma but has not been 
investigated for the cytotoxicity. In this study, we examined 
the Ad-delE1B55–mediated cytotoxicity with a panel of 
human mesothelioma cells and tested a possible combination 
with CDDP or PEM.
MATERIALS AND METHODS
Cells and Mice
Human mesothelioma, NCI-H2452, NCI-H2052, NCI-
H226, NCI-H28, and MSTO-211H cells were cultured with 
RPMI 1640 medium with 10% fetal calf serum. BALB/c nu/
nu mice were purchased from Japan SLC (Hamamatsu, Japan).
Ad Preparation
Ad were produced by deleting the 55-kDa molecule-
encoding E1B region. Replication-incompetent Ad express-
ing ß-galactosidase gene (Ad-LacZ) were prepared with 
an Adeno-X expression system (Takara, Shiga, Japan) with 
HEK293 cells.11 Amounts of Ad were expressed as virus par-
ticles (vps).
In Vitro Cytotoxicity and Cell Proliferation
Cells (5 × 103/well) in 96-well plates were cultured with 
Ad at different vp or chemotherapeutic agents. Cell viability 
was determined with a WST kit (Wako, Osaka, Japan), and 
the relative viability was calculated based on the absorbance 
without treatments. Viable cell numbers were counted with 
the trypan blue dye exclusion test. IC
50
 values and combina-
tory effects were examined with CalcuSyn software (Biosoft, 
Cambridge, United Kingdom). Combination index (CI) val-
ues were calculated based on the cell viability and were shown 
with fractions affected (Fa) at respective doses. A CI value 
equal to 1 denotes an additive interaction, above 1 antago-
nism, and below 1 synergism.
Western Blot Analysis
Cell lysate was subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, and the protein was trans-
ferred to a nylon filter and then hybridized with antibody (Ab) 
against Ad E1A, Mdm2 (Santa Cruz Biotech, Santa Cruz, CA), 
Ad hexon, Mad2 (Abcam, Cambridge, United Kingdom), p53 
(Lab vision, Fremont, CA), p27 (BD Biosciences, Franklin 
Lakes, NJ), caspase-3, cleaved caspase-3, caspase-8, cas-
pase-9, phosphorylated-p53 at Ser 15 and Ser 46, p21, Fas, 
FADD, pRb, phosphorylated pRb (Cell Signaling, Danvers, 
MA), or actin (Sigma-Aldrich, St. Louis, MO) as a control. 
Anti–caspase-8 and anti–caspase-9 Ab detect respective 
cleaved molecules.
Flow Cytometry and Cell Cycle
Cells were stained with anticoxsackie adenovirus recep-
tor (CAR) antibody (Upstate Charlottesville, VA) and were 
analyzed with FACSCalibur and CellQuest software (BD, San 
Jose, CA). For cell-cycle analyses, adherent and nonadherent 
cells were collected after Ad infection, fixed in 100% ethanol, 
treated with RNase (50 μg/ml), and stained with propidium 
iodide (50 μg/ml). Cell-cycle distribution was analyzed with 
flow cytometry.
Giemsa Staining and Apoptosis
Cells infected with Ad for 72 hours were treated with 
colcemid (10 μg/ml), incubated with hypotonic buffer, and 
stained with Giemsa solution. These cells were examined for 
apoptosis with the TdT-mediated dUTP nick end-labeling 
method using an in situ cell-death detection kit (Roche Applied 
Science, Indianapolis, IN) followed by a nuclear staining with 
Kernechtrot solution (Muto Pure Chemicals, Tokyo, Japan).
Animal Experiments
MSTO-211H cells (1 × 106) were injected into the pleu-
ral cavity, and the mice received Ad intrapleurally and/or 
CDDP or phosphate-buffered saline intravenously as a control 
on day 3. The tumor weights were measured on day 29. The 
animal experiments were approved by the animal experiment 
and welfare committee at Chiba University and were per-
formed according to the guideline on animal experiment.
RESULTS
Cytotoxicity of Ad-delE1B55
We examined cytotoxic activity of Ad-delE1B55 on 
mesothelioma cells, all of which are defective of the p14ARF 
and p16INK4A genes or of the corresponding transcriptions 
but possess the wild-type p53 (Fig. 1A). All the cells, except 
NCI-H2052 cells, were susceptible to Ad-delE1B55 but 
not to Ad-LacZ. The expression level of CAR molecules, 
the major type 5 Ad receptor, was low in NCI-H2052 cells 
(Fig. 1B), which was partly linked with the insensitivity to 
Ad-delE1B55. IC
50
 values based on the WST assay showed 
that NCI-H28 and MSTO-211H cells were most sensitive to 
Ad-delE1B55. We further examined proliferation kinetics of 
Ad-infected cells and demonstrated that numbers and viability 
of Ad-delE1B55–infected cells decreased after day 2, whereas 
uninfected or Ad-LacZ–treated cells did not (Fig. 2). These 
data suggested that Ad-delE1B55 infection induced growth 
arrest and cell death thereafter.
Expression of p53-Linked and 
Apoptosis-Linked Protein
We examined expression levels of p53-linked protein in 
NCI-H28 cells after Ad-delE1B55 infection (Fig. 3A). Early 
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viral E1A protein and late hexon protein became detectable 
at 24 and 48 hours after the infection, respectively. The infec-
tion up-regulated p53 expression levels and induced the phos-
phorylation at Ser 15 and then at 46 residues. Expression of 
cleaved 60 kDa Mdm2 moiety, which is a p53-binding form, 
was up-regulated but that of uncleaved 90 kDa Mdm2 was 
barely detected (data not shown). Anti-pRb Ab detected two 
bands corresponding to phosphoyrlated and dephosphory-
lated pRb, which migrated at high and low molecular weight, 
respectively, and probed the dephosphorylation more signifi-
cantly in Ad-delE1B55–infected than in Ad-LacZ–infected 
cells. The decreased pRb phosphorylation was confirmed 
by antiphosphorylated pRb Ab. Expressions of CDK inhibi-
tors, p21 and p27, were up-regulated in Ad-LacZ–infected 
cells but down-regulated in Ad-delE1B55–infected cells. 
Cells infected with Ad-LacZ became confluent with retarded 
growth under this experimental condition (Supplementary 
Figure 1, Supplementary Digital Content 1, http://links.lww.
com/JTO/A342), which consequently induced dephosphory-
lated pRb and up-regulated CDK inhibitors. We examined 
expression levels of the p53-linked protein in Ad-infected 
MSTO-211H cells, and the results were similar to those in 
NCI-H28 cells (Fig. 3C). Up-regulated expressions of p53 
and 60 kDa Mdm2, down-regulated expressions of pRb, phos-
phorylated pRB, p21, and p27, and cleavage of caspase-3 were 
also detected in MSTO-211H cells. Down-regulation of E1A 
and p53 phosphorylation was greater in MSTO-211H than in 
NCI-H28 cells.
We investigated possible apoptotic pathways, 
the extrinsic death receptor-mediated and the intrinsic 
mitochondria-mediated pathways (Fig. 3B). Both Ad-LacZ 
and Ad-delE1B55 infections increased caspase-8 expression, 
FIGURE 1. A, Cytotoxicity of Ad-delE1B55. Cells were infected with Ad-delE1B55 or Ad-LacZ, and the relative cell viability 
was calculated based on values of uninfected cells as 100%. SEs and IC50 (vp/cell) of Ad-delE1B55 are also shown. B, Expression 
levels of CAR molecules analyzed with flow cytometry. The bar values showed mean fluorescence intensity expressed with an 
arbitrary FL1 unit. HEK293 cells were used for a standard.
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but cleaved caspase-8 was detected in Ad-delE1B55–infected 
cells. Cleavage of caspase-9 was less significant compared 
with that of caspase-8 but was found to be greater at the level 
in Ad-delE1B55–infected than in Ad-LacZ–infected cells. 
Expression levels of Fas and FADD, localized upstream to 
caspase-8 activation, remained unchanged by Ad infection. 
We also examined possible apoptotic pathways in MSTO-
211H cells and detected the same expression patterns as found 
in NCI-H28 cells, except decreased Fas expression at 72 
hours (Fig. 3C). We found that expression levels of the BAX, 
the PUMA, and the NOXA genes, linked with the intrinsic 
pathways, were not up-regulated by Ad-delE1B55 infection 
FIGURE 2. A, Cell proliferation and (B), 
viability of Ad-delE1B55–infected cells. NCI-
H28 and MSTO-211H cells were infected 
with Ad (NCI-H28: 1 × 103, MSTO-211H: 
4.5 × 103 vp/cell), and the cell numbers 
and the viability were determined with the 
trypan blue dye exclusion test. Cells reached 
at the confluence were seeded to keep cell 
growing. SEs are shown. *p < 0.01, com-
pared with no treatment or Ad-LacZ group.
FIGURE 3. A and B, Ad-delE1B55–induced activation of p53 pathways. NCI-H28 and (C), MSTO-211H, cells were infected 
with Ad-delE1B55 (del-E1B) or Ad-LacZ (Ad-Z) at 1.5 × 103 vp/cell and cultured for the indicated times. Expression levels were 
analyzed with Western blot analyses. Actin was used as a control.
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(data not shown). These data collectively suggested that 
Ad-delE1B55 induced caspase activations primarily through 
the extrinsic pathways, although the upstream pathways of 
caspase-8 remained unknown.
Cell-Cycle Changes with Increased Hyperploidy
We investigated cell-cycle changes after Ad infection with 
NCI-H28 and MSTO-211H cells (Fig. 4; Table 1). Ad-LacZ 
infection induced minimal changes with slightly increased 
G2/M-phase fractions in NCI-H28 cells. Ad-delE1B55 infec-
tion gradually increased sub-G1 populations, which was 
notable in MSTO-211H cells. Before the increased sub-G1 
fraction, a fraction with more than 4N populations (hyper-
ploidy) increased in a time-dependent manner particularly in 
NCI-H28 cells. These results suggest that cells in the hyper-
ploid fraction were subjected to apoptotic cell death.
We investigated whether the hyperploidy was attribut-
able to any changes at a chromosomal level. We first examined 
chromosomal numbers at M-phase with colcemid treatment. 
NCI-H28 cells had increased chromosome numbers (average ± 
SE: 83.50 ± 0.28), and the numbers remain unchanged after 
Ad-LacZ (84.86 ± 0.44) or Ad-delE1B55 (85.50 ± 0.42) 
infection. Constant chromosome numbers at M-phase can be 
because of a possibility that Ad-delE1B55–infected cells with 
hyperploid fractions did not enter into M-phase but stayed 
before G2-phase. We then examined any gene copy number 
changes with an array comparative genomic hybridization 
technique (Supplementary Figure 2, Supplementary Digital 
Content 2, http://links.lww.com/JTO/A343). Differential 
hybridization between Ad-delE1B55–infected and uninfected 
NCI-H28 or MSTO-211H cells did not reveal any gross chro-
mosomal or gene copy number alternations. Furthermore, 
expression levels of Mad2, which inhibits chromosomal 
segregations in the spindle checkpoint, remained unchanged 
(Fig. 3B and 3C). We also examined nuclear morphology 
with the Giemsa staining method (Fig. 5A). Ad-delE1B55–
infected cells demonstrated two characteristic patterns: 
an enlarged nuclear configuration and a small condensed 
nucleus, which were not detected in Ad-LacZ–infected cells. 
FIGURE 4.  Representative profiles of 
cell-cycle analyses. Cells were treated with 
Ad-delE1B55 or Ad-LacZ (NCI-H28: 1 × 103, 
MSTO-211H: 4.5 × 103 vp/cell), or untreated 
for 72 hours.
FIGURE 5. A, Nuclear morphological 
changes induced by Ad-delE1B55. NCI-
H28 cells were infected with Ad (1 × 103 vp/
cell) followed by the Giemsa staining. In 
Ad-delE1B55–treated cells, small and highly 
condensed nuclei (solid arrow) and large and 
uncondensed nuclei (open) were detected. 
B, NCI-H28 cells infected with Ad (1 × 103 vp/
cell) were examined for apoptosis with the 
TUNEL assay and stained with Kernechtrot 
solution to visualize nuclei. TUNEL, termi-
nal deoxynucleotidyl transferase–mediated 
deoxyuridine triphosphate-biotin nick 
end-labeling.
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We demonstrated that the cells with condensed nuclei were 
subjected to apoptosis (Fig. 5B). These data collectively sug-
gested that Ad-delE1B55 infection increased nuclear DNA 
contents followed by pyknotic and apoptotic changes without 
gross chromosomal changes.
Combinatory Effects
We investigated possible combinatory cytotoxic effects 
produced by Ad-delE1B55 and anticancer agents (Fig. 6). 
NCI-H28 and MSTO-211H cells were tested with differ-
ent doses of CDDP or PEM to calculate IC
50
 values (Fig. 6A 
and C). We then examined the susceptibility to Ad-delE1B55 
in combination with the agents and calculated CI values at 
various Fa points. A combination of Ad-delE1B55 and CDDP 
produced synergistic effects in MSTO-211H cells at all the Fa 
points tested and either synergistic or additive effects in NCI-
H28 cells at Fa below 0.75 (Fig. 6B). Ad-delE1B55 and PEM 
acted synergistically in NCI-H28 and MSTO-211H cells in 
the range of Fa 0.45 to 0.95 and Fa 0.65 to 0.95, respectively, 
and additive effects in lower Fa points (Fig. 6D). These results 
suggest that a combinatory use of Ad-delE1B55 and CDDP 
or PEM achieved synergistic cytotoxic effects in most cases 
of MSTO-211H cells and less significantly in NCI-H28 cells.
We also examined expression levels of p53 and the 
phosphorylation and caspase-3 cleavages in the combination 
(Fig. 6E). MSTO-211H cells treated with both Ad-delE1B and 
CDDP showed up-regulated p53 expression, p53 phosphory-
lation, and caspase-3 cleavage at a greater level than those 
treated with Ad-delE1B or CDDP. These data suggests that the 
combination augmented p53-mediated apoptotic processes. 
Cell-cycle analyses showed that the combinatory treatment 
increased sub-G1 populations greater than Ad-delE1B55 or 
CDDP treatment (Supplementary Table 1, Supplementary 
Digital Content 3, http://links.lww.com/JTO/A344). 
Interestingly, the combination amplified hyperploid fractions, 
but a role of CDDP in the enhanced hyperploidy is currently 
unknown.
In Vivo Antitumor Effects
We investigated the antitumor effects of Ad-delE1B55 
and a combinatory effect with CDDP in an orthotopic xeno-
graft model (Table 2). Ad-delE1B55 administration did not 
produce the antitumor effects at a low dose (1 × 1010 vp) but 
achieved the effects at a high dose (8 × 1010 vp). Tumor growth 
of the mice treated with Ad-delE1B55 (1 × 1010 vp) plus 
CDDP was more inhibited than that of the group treated with 
either Ad-delE1B55 or CDDP. The high-dose Ad-delE1B55 
suppressed the tumor growth to a great extent, and conse-
quently the combination effects with CDDP were not detected 
with statistical significance, although the combination pro-
duced better therapeutic effects than CDDP alone. In contrast, 
Ad-LacZ did not achieve antitumor effects or the combina-
tory effects. An intermediate Ad dose (3 × 1010 and 6 × 1010 vp) 
produced combinatory effects with CDDP (Supplementary 
Table 2, Supplementary Digital Content 4, http://links.lww.
com/JTO/A345). Mice body weights were not retarded by Ad 
administration, suggesting that mice tolerated intrapleural Ad 
injections.
DISCUSSION
To our knowledge, our study first demonstrated the 
cytotoxicity of Ad-delE1B55 to p14/p16-defective meso-
thelioma. Ad-delE1B55 up-regulated p53 probably through 
viral E1A and phosphorylated p53 at Ser 15 and 46 residues, 
FIGURE 6. A, Combinatory effects of Ad-delE1B55 and 
CDDP or PEM. Cells were treated with different doses of 
CDDP or (C) PEM , and the relative cell viabilities were cal-
culated based on values of untreated cells as 100%. B, Cells 
were also treated with various vp of Ad-delE1B55 and con-
centrations of CDDP or (D), PEM . CIs were calculated with 
CalcuSyn software and plotted in respective Fa points. SEs are 
shown. E, MSTO-211H cells were treated with Ad-delE1B55 
(1.5 × 103 vp/cell) and/or with CDDP (10 μM). Expression 
levels of the indicated proteins were analyzed with Western 
blot analyses. Actin was used as a control. CDDP, cis-diam-
minedichloroplatinum; PEM, pemetrexed.
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both of which are linked with cell-cycle arrest and apoptosis, 
respectively. The mechanism for p53 phosphorylation without 
DNA damages is currently unknown, but the viral replication 
itself may induce the phosphorylation because Ad-LacZ did 
not phosphorylate endogenous p53. Cleaved 60 kDa Mdm2 
binds to p53 and inhibits degradation, which can contribute 
to the p53 upregulation.12 We scarcely detected the full-length 
90 kDa molecules despite an assumption that the full-length 
molecules can be overexpressed as a result of deficit of Mdm2-
inhibiting p14. Activation of p53 pathways by Ad-delE1B55 
did not augment p21 expression. Increased p21 was inhibitory 
to cell death, and decreased p21 rather promoted Ad replica-
tion and cell death.13 CDK expressions were thus not directly 
linked with p53 activation. The down-regulated CDK expres-
sions were also associated with decreased pRb phosphoryla-
tion, which inhibits cell-cycle progression into S-phase. These 
data collectively suggest that Ad-delE1B55 restored p53 and 
pRb functions as a tumor suppressor.
Ad-delE1B55 induced cell death, which was evidenced 
by increased sub-G1 fraction and loss of viability. Caspase-3 
and caspase-8 were cleaved, but caspase-9 cleavage was less 
significant. Moreover, transcription of the Puma, the Noxa, 
and the BAX genes did not increase (data not shown). These 
data indicated that the cell death was induced primarily by 
the extrinsic pathways and involvement of the intrinsic path-
way was relatively minor. Expression levels of Fas and FADD 
remain unchanged, and the upstream signaling of the extrinsic 
pathways needs further investigations. Moreover, our prelimi-
nary data showed that expression levels of some autophagy 
markers such as Atg5 remained unchanged after Ad-delE1B55 
infection, suggesting that involvement of autophagy was less 
likely in cell death.
Flow cytometrical analyses demonstrated increase 
of hyperploid populations followed by augmented sub-
G1 fractions. Cherubini et al.14 showed that Ad-delE1B55 
induced hyperlploidy in the p53 wild-type nontumorous cells 
and demonstrated increased expression of Mad2, a major 
component of M-phase checkpoint. The study indicated 
that wild-type Ad did not induce hyperploidy, eliminating 
a possibility that hyperploidy was caused by amplified viral 
TABLE 1.  Cell-Cycle Distribution after Ad Infection 
Cells Time (hr) Treatmenta Cell-Cycle Distribution (%±SE)b
Sub-G1 G1 S G2/M >4N
NCI-H28 24 (—) 0.15 ± 0.03 65.00 ± 3.14 18.33 ± 0.74 16.81 ± 2.34 0.24 ± 0.09
Ad-LacZ 0.14 ± 0.04 56.52 ± 0.22 18.31 ± 0.33 24.83 ± 0.19 0.57 ± 0.10
Ad-delE1B55 0.17 ± 0.04 63.52 ± 0.43 16.47 ± 0.10 18.11 ± 0.54 2.07 ± 0.09c
48 (—) 0.13 ± 0.04 65.94 ± 0.23 14.75 ± 0.09 18.61 ± 0.15 0.90 ± 0.06
Ad-LacZ 0.23 ± 0.05 62.44 ± 0.50 8.35 ± 0.07 27.37 ± 0.53 1.83 ± 0.13
Ad-delE1B55 0.61 ± 0.08c 28.14 ± 0.00 17.23 ± 0.56 24.28 ± 0.45 30.25 ± 0.05c
72 (—) 0.13 ± 0.03 75.55 ± 0.22 9.71 ± 0.28 13.44 ± 0.45 1.15 ± 0.04
Ad-LacZ 0.25 ± 0.02 71.07 ± 0.04 3.25 ± 0.08 24.11 ± 0.30 1.51 ± 0.20
Ad-delE1B55 1.09 ± 0.05c 30.87 ± 0.28 6.19 ± 0.19 13.94 ± 0.08 48.21 ± 0.44c
MSTO-211H 24 (—) 1.27 ± 0.03 61.78 ± 0.74 13.62 ± 0.32 21.85 ± 0.27 1.48 ± 0.16
Ad-LacZ 1.37 ± 0.09 60.33 ± 0.40 14.66 ± 0.26 22.37 ± 0.34 1.46 ± 0.05
Ad-delE1B55 1.37 ± 0.05 62.67 ± 0.45 12.47 ± 0.10 21.33 ± 0.32 2.24 ± 0.14c
48 (—) 0.66 ± 0.06 79.43 ± 0.45 6.61 ± 0.24 12.70 ± 0.53 0.72 ± 0.02
Ad-LacZ 1.05 ± 0.04 79.11 ± 0.27 5.51 ± 0.19 13.26 ± 0.06 1.19 ± 0.04
Ad-delE1B55 3.70 ± 0.12c 68.77 ± 0.65 6.95 ± 0.15 13.25 ± 0.28 7.53 ± 0.45c
72 (—) 2.15 ± 0.05 89.09 ± 0.13 1.82 ± 0.10 6.45 ± 0.06 0.61 ± 0.04
Ad-LacZ 2.39 ± 0.18 87.21 ± 0.26 1.84 ± 0.05 7.99 ± 0.09 0.65 ± 0.07
Ad-delE1B55 10.13 ± 0.42c 57.31 ± 0.60 5.95 ± 0.24 9.33 ± 0.28 17.76 ± 0.38c
a Cells were infected with Ad-LacZ or Ad-delE1B55 (H28: 1 × 103, 211H: 4.5 × 103 vp/cell) and cultured for 24 to 72 hr.
b Cell-cycle profiles were analyzed with flow cytometry. Mean percentages with SEs are shown (n = 3).
c p < 0.01, compared with no treatment or Ad-LacZ group.
AD, adenovirus;
TABLE 2.  Effects of Ad-delE1B55 and CDDP on 
Mesothelioma in Nude Mice 
Ad (vp/mouse) 
Treatmenta
Tumor Weight (mg)  
(average ± SE)b
CDDP (−)a CDDP (+)a
Exp 1 (—) 273 ± 231 149 ± 221,4
Ad-LacZ (1 × 1010) 271 ± 342 124 ± 92
Ad-delE1B (1 × 1010) 225 ± 523 47 ± 133,4
Exp 2 (—) 278 ± 445 112 ± 285,8
Ad-LacZ (8 × 1010) 244 ± 106,7 76 ± 306,9
Ad-delE1B (8 × 1010) 22 ± 87 4 ± 18,9
a Mice were injected with MSTO-211H (1 × 106) into the pleural cavity (day 1) and 
were treated with intrapleural Ad (day 3) and/or intraperitoneal CDDP (0.12 mg/mouse) 
administrations (day 3). Phosphate-buffered saline was also injected as a control in Ad 
(−) or CDDP (−) groups.
b Tumor weight was measured on day 29. Average with SEs are shown (n = 6–7). 
p < 0.01,1–3,5–8 p < 0.05.4,9
Ad, adenovirus; CDDP, cis-diamminedichloroplatinum.
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DNA. Our preliminary data also showed that the wild-type 
Ad minimally induced hyperploidy and rapidly increased 
sub-G1 fractions. The current study showed that Mad2 
expression and chromosomal numbers at M-phase remained 
unchanged. We thereby speculate that Ad-delE1B55–
infected cells could not enter into M-phase and the cell cycle 
stopped before G2 checkpoint. Aberrant mitosis is known to 
lead to cell death, and the morphological characteristics such 
as enlarged and multinucleated cells are hallmarks of the 
mitotic catastrophe.15 The current data instead showed that 
cells with enlarged and condensed nuclei became apoptotic, 
and array comparative genomic hybridization data excluded 
possible amplified chromosomal regions. A molecular 
basis of the Ad-induced hyperploidy is therefore currently 
unknown.
We demonstrated combinatory effects of Ad-delE1B55 
and CDDP or PEM. Anticancer agents can suppress viral rep-
lication by inhibiting protein synthesis in host cells, but our 
previous study demonstrated that it was not always the case.11 
Ad-delE1B55 infection increased susceptibility of mesothe-
lioma to CDDP and to a lesser extent to PEM. The differen-
tial effect of Ad-delE1B55 may be linked with up-regulated 
p53 expression and pRb dephosphorylation. Up-regulated 
p53 resulted in enhanced sensitivity to anticancer agents by 
augmenting apoptotic pathways.16 The current study dem-
onstrated that the combinatory use of Ad-delE1B55 and 
CDDP induced p53 phosphoylation and caspase-3 cleavage 
greater than each agent alone. Ad-delE1B55 also inhibited 
cell-cycle progression through pRb dephosphorylation, 
which decreases effects of agents inhibiting DNA replica-
tion. PEM, inhibiting DNA synthesis, is thus less effective 
compared with CDDP.
We demonstrated combinatory effects of Ad-delE1B55 
and CDDP in an orthotopic model, which suggests clinical 
feasibility. Mesothelioma patients often have pleural effusion, 
and the tumors extend along the thoracic cavity. Intrapleural 
injection makes Ad spread the cavity lining and increased the 
infectivity. Moreover, pleural administration has less chance 
of hepatotoxicity, the major Ad toxicity, because of multiple 
barriers for Ad to spread into liver. The current study however 
suggested that low CAR-expressing mesothelioma could be 
resistant to Ad-mediated cytotoxicity.
In summary, the current study demonstrated that 
Ad-delE1B55 was a possible agent for mesothelioma through 
activating p53 pathways and produced combinatory antitumor 
effects with the first-line chemotherapeutic agents currently 
used.
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